SciSparc and Clearmind Innovate Mental Health Treatment

SciSparc Ltd. (SPRC) has released an update.

SciSparc Ltd., in collaboration with Clearmind Medicine Inc., has announced the publication of an international patent application for a novel MDMA-based treatment aimed at improving safety and efficacy in mental health and addiction therapies. Their combined approach seeks to address FDA concerns by integrating MDMA with N-Acylethanolamines, promising advancements in clinical treatments of mental disorders and addictions. SciSparc, a clinical-stage pharmaceutical company, continues to focus on cannabinoid-based pharmaceuticals, while Clearmind concentrates on psychedelic-derived therapeutics for underserved health problems.

For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.